Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 5:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 1,620 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Retinal Disease Clear all
Not listed Phase 2 Interventional Accepts healthy volunteers

Intravitreal Aflibercept for the Prevention of Proliferative Vitreoretinopathy Following Retinal Detachment Repair

NCT04580147
View directory record Official record
Conditions
Retinal Detachment With Multiple Breaks, Unspecified Eye, Proliferative Vitreoretinopathy
Interventions
Intravitreal aflibercept injection, Sham control
Drug · Other
Lead sponsor
M. Ali Khan, MD
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 3, 2022 · Synced Oct 29, 2026, 5:05 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Data Gathering for A10900

NCT07149740
View directory record Official record
Conditions
Retinal Disease, Healthy, Glaucoma, Corneal Diseases
Interventions
OCT
Device
Lead sponsor
Optos, PLC
Industry
Eligibility
22 Years and older
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
4
States / cities
Anaheim, California • West Hartford, Connecticut • Wellesley Hills, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 29, 2026, 5:05 PM EDT
Not listed Phase 1 Interventional

Topotecan Episcleral Plaque for Treatment of Retinoblastoma

NCT04156347
View directory record Official record
Conditions
Retinoblastoma
Interventions
Episcleral Topotecan
Drug
Lead sponsor
Targeted Therapy Technologies, LLC
Industry
Eligibility
Up to 18 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 31, 2023 · Synced Oct 29, 2026, 5:05 PM EDT
Terminated Phase 2 Interventional Results available

A Study Assessing the Long-Term Safety and Tolerability of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

NCT04607148
View directory record Official record
Conditions
Macular Degeneration, Age-Related, Geographic Atrophy
Interventions
Galegenimab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
60 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
48
States / cities
Bakersfield, California • Encino, California • Fullerton, California + 43 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Oct 29, 2026, 5:05 PM EDT
Completed No phase listed Observational

Evaluation and Treatment of Patients With Retinal Disease

NCT00005784
View directory record Official record
Conditions
Retinal Disease
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
10 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 29, 2026, 5:05 PM EDT
Terminated Phase 3 Interventional Results available

PROMINENT-Eye Ancillary Study (Protocol AD)

NCT03345901
View directory record Official record
Conditions
Diabetic Retinopathy, Diabetic Macular Edema
Interventions
Pemafibrate, Placebo
Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
69
States / cities
Phoenix, Arizona • Campbell, California • Glendale, California + 52 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 29, 2026, 5:05 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR)

NCT05066230
View directory record Official record
Conditions
Non-proliferative Diabetic Retinopathy
Interventions
KSI-301, Sham injection
Drug · Other
Lead sponsor
Kodiak Sciences Inc
Industry
Eligibility
18 Years and older
Enrollment
253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
46
States / cities
Phoenix, Arizona • Beverly Hills, California • Fullerton, California + 42 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2024 · Synced Oct 29, 2026, 5:05 PM EDT
Completed No phase listed Observational

AMD Ryan Initiative Study (ARIS)

NCT03092492
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
55 Years to 120 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 29, 2026, 5:05 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total PVD in Subjects With NPDR

NCT02681809
View directory record Official record
Conditions
Diabetic Retinopathy, Posterior Vitreous Detachment, Disease Progression
Interventions
ocriplasmin 0.0625mg, ocriplasmin 0.125mg, Sham injection
Drug
Lead sponsor
ThromboGenics
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
9
States / cities
Phoenix, Arizona • Campbell, California • Irvine, California + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Oct 29, 2026, 5:05 PM EDT
Active, not recruiting Phase 2 Interventional

A Study Comparing Two Doses of AGTC-501 in Male Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (SKYLINE)

NCT06333249
View directory record Official record
Conditions
X-Linked Retinitis Pigmentosa
Interventions
rAAV2tYF-GRK1-RPGR
Biological
Lead sponsor
Beacon Therapeutics
Industry
Eligibility
8 Years to 50 Years · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
6
States / cities
Jacksonville, Florida • Boston, Massachusetts • Cincinnati, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Oct 29, 2026, 5:05 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Self-Monitoring OCT

NCT07584798
View directory record Official record
Conditions
Obtaining OCT (Optical Coherence Tomography) Images
Interventions
Self-administered OCT imaging system, Technician-acquired OCT imaging
Procedure
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 29, 2026, 5:05 PM EDT
Completed Phase 2 Interventional

Assessment of Intravitreous Injections of Vitrase for Inducing Posterior Vitreous Detachment

NCT00198471
View directory record Official record
Conditions
Vitreous Detachment, Diabetic Retinopathy
Interventions
Vitrase
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
50 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
4
States / cities
Beverly Hills, California • New York, New York • McAllen, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2013 · Synced Oct 29, 2026, 5:05 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Novel Retinal Imaging Biomarkers in Early Alzheimer's Disease

NCT01937221
View directory record Official record
Conditions
Mild Cognitive Impairment, Mild to Moderate Cognitive Impairment
Interventions
spectral-domain optical coherence tomography (SD-OCT)
Other
Lead sponsor
Duke University
Other
Eligibility
55 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 31, 2019 · Synced Oct 29, 2026, 5:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Rubeosis Anti-VEGF (RAVE) Trial for Ischemic Central Retinal Vein Occlusion

NCT00406471
View directory record Official record
Conditions
Ischemic Central Retinal Vein Occlusion
Interventions
Ranibizumab (Lucentis)
Drug
Lead sponsor
Greater Houston Retina Research
Other
Eligibility
19 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 14, 2013 · Synced Oct 29, 2026, 5:05 PM EDT
Completed Phase 2 Interventional

A Study of the Efficacy and Safety of KUS121 in Participants With Acute Non-Arteritic Central Retinal Artery Occlusion (CRAO)

NCT06178055
View directory record Official record
Conditions
Central Retinal Artery Occlusion
Interventions
KUS121 high dose, KUS121 low dose, Sham procedure
Drug
Lead sponsor
Kyoto Drug Discovery and Development Co., Ltd.
Industry
Eligibility
20 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
11
States / cities
Encino, California • Huntington Beach, California • Oakland, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 29, 2026, 5:05 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Genetic Study of Age-Related Macular Degeneration

NCT00357578
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
50 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 29, 2026, 5:05 PM EDT
Completed Phase 1 Interventional

Investigating the Effect of Vitamin A Supplementation on Retinitis Pigmentosa

NCT00065455
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
Vitamin A
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 29, 2026, 5:05 PM EDT
Recruiting Phase 2 Interventional

A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251

NCT05626114
View directory record Official record
Conditions
Geographic Atrophy
Interventions
OpRegen
Biological
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
15
States / cities
Beverly Hills, California • Sacramento, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 29, 2026, 5:05 PM EDT
Completed No phase listed Observational

Study of the Effects of Supplements on Eye Disease in Participants From the Age-Related Eye Disease Study

NCT01915238
View directory record Official record
Conditions
AMD, Age- Related Macular Degeneration
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
50 Years to 85 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Bethesda, Maryland • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Oct 29, 2026, 5:05 PM EDT
Completed Not applicable Interventional

The Safety and Effectiveness of Ganciclovir Used Alone or in Combination With Granulocyte-Macrophage Colony Stimulating Factor in the Treatment of Cytomegalovirus (CMV) of the Eye in Patients With AIDS

NCT00000989
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Zidovudine, Sargramostim, Ganciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1992
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 29, 2026, 5:05 PM EDT
Completed No phase listed Observational

Retinitis Pigmentosa Clinical Measures and Repeatability Testing of Potential Outcome Measures

NCT03845218
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
12 Years to 100 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 29, 2026, 5:05 PM EDT
Completed Not applicable Interventional

Effect of Omega-3-fatty Acids on Blood Levels Omega-3 Fatty Acids in Patients With Age-related Macular Degeneration

NCT01653184
View directory record Official record
Conditions
Macular Degeneration
Interventions
Omega-3 fatty acid
Dietary Supplement
Lead sponsor
Wills Eye
Other
Eligibility
55 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
4
States / cities
Cherry Hill, New Jersey • Bethlehem, Pennsylvania • Huntingdon Valley, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2016 · Synced Oct 29, 2026, 5:05 PM EDT
Completed Phase 1Phase 2 Interventional

Prophylactic Ranibizumab for Exudative Age-Related Macular Degeneration

NCT02302989
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
Ranibizumab 0.5mg
Drug
Lead sponsor
Leonard Feiner, MD, PhD
Other
Eligibility
50 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Teaneck, New Jersey • Vauxhall, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Oct 29, 2026, 5:05 PM EDT
Completed Phase 1Phase 2 Interventional

Combretastatin A4 Phosphate in Patients With Neovascular Age-Related Macular Degeneration

NCT01570790
View directory record Official record
Conditions
Combretastatin A4 Phosphate, Age-related Macular Degeneration, AMD, CNV, Choroidal Neovascularization
Interventions
Combretastatin A-4 Phosphate
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Oct 29, 2026, 5:05 PM EDT